Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. At December 31, 2019, two customers accounted for 89% of the Company’s total accounts receivable. At December 31, 2018, three customers accounted for approximately 95% of the Company’s consolidated accounts receivable.

For the year ended December 31, 2019, three customers totaled 70% of the Company’s consolidated revenues. For the year ended December 31, 2018, BPC represented 56% of the Company’s consolidated revenues, and two other customers totaled 31% of the Company’s consolidated revenues.

The Company purchases substantially all of its raw material plasma from Grifols. For the year ended December 31, 2019, plasma purchases from Grifols totaled approximately $28.6 million, representing approximately 82% of the Company’s total inventory purchases. For the year ended December 31, 2018, plasma purchases from BPC totaled $7.8 million, or approximately 71% of the Company’s total inventory purchases.